Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andre Goy

Showing results (71-80 of 164) with videos related to

Pageof 17
Sort By:
Journal of Clinical Pharmacology|June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignanciesTae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.
Journal of Hematology & Oncology|November 4, 2017
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)Michael Wang, Stephen J Schuster, Tycel Phillips, et al.
Journal of Ovarian Research|April 3, 2016
The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancerAyala Tamir, Anju Gangadharan, Sakshi Balwani, et al.
Leukemia & Lymphoma|June 25, 2016
FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS studyLale Kostakoglu, Andre Goy, Giovanni Martinelli, et al.
Blood|July 24, 2019
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCLAndre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, et al.
British Journal of Haematology|April 30, 2015
Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trialAndre Goy, Sevgi Kalayoglu Besisik, Johannes Drach, et al.
Oncotarget|August 27, 2016
Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicinePoonam Nagpal, Mohamed R Akl, Nehad M Ayoub, et al.
British Journal of Haematology|August 24, 2017
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studiesSimon Rule, Martin Dreyling, Andre Goy, et al.
Journal of Oncology|March 1, 2022
Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the PandemicCatherine Lai, Arnold L Potosky, Colleen McGuire, et al.
Leukemia & Lymphoma|March 16, 2013
Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphomaAnthony Mato, Tatyana Feldman, Tania Zielonka, et al.
Pageof 17

Showing results (71-80 of 164) with videos related to

Sort By:
Pageof 17
Journal of Clinical Pharmacology|June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignanciesTae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.
Journal of Hematology & Oncology|November 4, 2017
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)Michael Wang, Stephen J Schuster, Tycel Phillips, et al.
Journal of Ovarian Research|April 3, 2016
The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancerAyala Tamir, Anju Gangadharan, Sakshi Balwani, et al.
Leukemia & Lymphoma|June 25, 2016
FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS studyLale Kostakoglu, Andre Goy, Giovanni Martinelli, et al.
Blood|July 24, 2019
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCLAndre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, et al.
British Journal of Haematology|April 30, 2015
Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trialAndre Goy, Sevgi Kalayoglu Besisik, Johannes Drach, et al.
Oncotarget|August 27, 2016
Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicinePoonam Nagpal, Mohamed R Akl, Nehad M Ayoub, et al.
British Journal of Haematology|August 24, 2017
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studiesSimon Rule, Martin Dreyling, Andre Goy, et al.
Journal of Oncology|March 1, 2022
Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the PandemicCatherine Lai, Arnold L Potosky, Colleen McGuire, et al.
Leukemia & Lymphoma|March 16, 2013
Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphomaAnthony Mato, Tatyana Feldman, Tania Zielonka, et al.
Pageof 17